Mu, Ruipeng
Yuan, Jiaqi
Huang, Yue
Meissen, John K.
Mou, Si
Liang, Meina
Rosenbaum, Anton I. http://orcid.org/0000-0003-1939-951X
Article History
Accepted: 8 February 2022
First Online: 1 April 2022
Declarations
:
: No sources of funding were used to conduct this study or prepare this manuscript.
: All authors contributed to the manuscript preparation. Ruipeng Mu and Jiaqi Yuan contributed equally to this work. Anton I. Rosenbaum, Ruipeng Mu, and Jiaqi Yuan contributed to the idea of the article. Ruipeng Mu, Jiaqi Yuan, Yue Huang, John K. Meissen, and Si Mou contributed to the drafting and critical revision of this work. Meina Liang and Anton I. Rosenbaum contributed to the critical revision of this work. All authors read and approved the final manuscript.
: Ruipeng Mu, Jiaqi Yuan, Yue Huang, John K. Meissen, Si Mou, Meina Liang, and Anton I. Rosenbaum are employees and shareholders of AstraZeneca.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.